

Primary Hyperparathyroidism Committee meeting 12

Date: 10/09/2018

Location: NGC Boardroom

Minutes: Confirmed

Committee members present:		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 4)
Terry Aspray (TA)		(Present for notes 1 – 4)
Parijat De (PD)		(Present for notes 1 – 4)
Joy Foster (JF)		(Present for notes 1 – 4)
Neil Gittoes (NG)		(Present for notes 1 – 4)
Imran Jawaid (IJ)		(Present for notes 1 – 4)
Fausto Palazzo (FP)		(Present for notes 1 – 4)
Peter Selby (PS)		(Present for notes 1 – 4)
Anthony Skene (AS)		(Present for notes 1 – 4)
Nicholas Thomson (NT)		(Present for notes 1 – 4)

In attendance:		
Katie Broomfield (KB)	Project Manager	(Present for notes 1 – 4)
Emma Cowles (EC)	Senior Health Economist	(Present for notes 1 – 4)
Ian Mather (IM)	Business Analyst	(Present for notes 1 – 4)
Sharangini Rajesh (SR)	Senior Research Fellow	(Present for notes 1 – 4)
Melina Vasileiou (MV)	Research Fellow	(Present for notes 1 – 4)
Kyann Zhang (KZ)	Health Economist	(Present for notes 1 – 4)
Judith McBride (JMB)	Senior Medical Editor, NICE	(Present for notes 3.6 – 4)
Sharon Swain (SS)	Associate Director/Guideline Lead, NGC	(Present for notes 1 – 4)

Apologies:		
Jill Cobb (JC)	Information Specialist, NGC	

Julie Cox	Committee member
Nick Staples (NS)	Guideline Commissioning Manager, NICE

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the twelfth meeting on primary hyperparathyroidism.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to declare verbally any interests that have arisen since application. The following new interests were received for this meeting:

Committee Declarations of Interest			
N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published Sept 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
NG	Chairing international advisory board in Middle East for pharmaceutical company marketing vitamin D preparations. Fee received for service.	Direct financial non-specific	Declare and participate
	Advisory board member to the National Osteoporosis Advisory Group (NOGG)	Direct non-financial non-specific	
PS	Advisory board member to the National Osteoporosis Advisory Group (NOGG)	Direct non-financial non-specific	Declare and participate
NICE DOI policy classifications are: <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific 			

The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that one of the original DOIs was in conflict with the

agenda topics and clinical questions under discussion at the meeting:

FP: Based on the need for the committee member's expertise, in this instance NICE has confirmed that the individual can remain for discussion but participation is limited to responding to questions from the chair or other members.

3. Presentations and discussion

3.1 The minutes and meeting notes from GC10&11 were confirmed to be an accurate record of the discussions.

3.2 MV presented the top-up search evidence.

3.3 KZ led a discussion on the economic model results.

3.4 SS led a discussion on the research recommendations.

3.5 IM gave a presentation on resource impact.

3.6 SS led a discussion on the draft recommendations.

4. Any other business

Next steps discussed and action points agreed.

Date of next meeting: 29/01/2019

Location of next meeting: Royal College of Physicians